Literature DB >> 1600596

Synergistic interaction of cyclosporin A and verapamil on vincristine and daunorubicin resistance in multidrug-resistant human leukemia cells in vitro.

K Osann1, P Sweet, L M Slater.   

Abstract

We studied the effects of cyclosporin A and verapamil on the modulation of vincristine and daunorubicin resistance in a multidrug-resistant subline of human T-cell acute lymphatic leukemia GM3639. Our results show that cyclosporin A is more effective than verapamil as a modulator of the high degree of primary vincristine resistance and the low degree of daunorubicin cross-resistance expressed by this cell line. Isobologram analysis revealed that the combined modulators act synergistically in correcting both vincristine and daunorubicin resistance.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1600596     DOI： 10.1007/bf00686409

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  14 in total

1.  Correspondence re: Xiu F. Hu et al., Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines. Cancer Res., 50: 2953-2957, 1990.

Authors:  B L Samuels; M J Ratain
Journal:  Cancer Res       Date:  1991-03-15       Impact factor: 12.701

2.  Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity.

Authors:  G G Steel; M J Peckham
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-01       Impact factor: 7.038

3.  Chemotherapeutic drug sensitivity testing of human leukemia cells in vitro using a semiautomated fluorometric assay.

Authors:  R Larsson; P Nygren; M Ekberg; L Slater
Journal:  Leukemia       Date:  1990-08       Impact factor: 11.528

4.  Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs.

Authors:  D M Woodcock; S Jefferson; M E Linsenmeyer; P J Crowther; G M Chojnowski; B Williams; I Bertoncello
Journal:  Cancer Res       Date:  1990-07-15       Impact factor: 12.701

5.  Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines.

Authors:  X F Hu; T J Martin; D R Bell; M de Luise; J R Zalcberg
Journal:  Cancer Res       Date:  1990-05-15       Impact factor: 12.701

6.  Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma.

Authors:  L M Slater; S L Murray; M W Wetzel; R M Wisdom; E M DuVall
Journal:  J Clin Invest       Date:  1982-11       Impact factor: 14.808

7.  Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1981-05       Impact factor: 12.701

8.  Verapamil potentiation of VP-16-213 in acute lymphatic leukemia and reversal of pleiotropic drug resistance.

Authors:  L M Slater; S L Murray; M W Wetzel; P Sweet; M Stupecky
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro.

Authors:  L M Slater; P Sweet; M Stupecky; S Gupta
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

10.  Verapamil and cyclosporin A potentiate the effects of chemotherapeutic drugs in the human medullary thyroid carcinoma TT cell line not expressing the 170 kDa P-glycoprotein.

Authors:  R Larsson; P Nygren
Journal:  Cancer Lett       Date:  1990-11-05       Impact factor: 8.679
View more
  5 in total

1.  Differential effectiveness of a range of novel drug-resistance modulators, relative to verapamil, in influencing vinblastine or teniposide cytotoxicity in human lymphoblastoid CCRF-CEM sublines expressing classic or atypical multidrug resistance.

Authors:  B T Hill; L K Hosking
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

2.  Multiple resistance modulators combined with carboplatin for resistant malignancies: a pilot study.

Authors:  D J Stewart; R Goel; M C Cripps; S Huan; J Yau; S Verma
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 3.  Pharmacologic circumvention of multidrug resistance.

Authors:  J M Ford; W N Hait
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

4.  Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents.

Authors:  C Pascaud; M Garrigos; S Orlowski
Journal:  Biochem J       Date:  1998-07-15       Impact factor: 3.857

5.  Modulation of anthracycline accumulation and metabolism in rat hepatocytes in culture by three revertants of multidrug resistance.

Authors:  M A Le Bot; D Kernaleguen; J Robert; M Berlion; C Riché
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.